89$/KG
Product Detailed Description
liposomal Vitamin B3 Niacin 80% is a premium-grade dietary supplement ingredient delivering nicotinic acid in an advanced liposomal delivery system. Niacin (CAS 59-67-6), also known as nicotinic acid, pyridine-3-carboxylic acid, or vitamin B3, is a water-soluble vitamin with the molecular formula C₆H₅NO₂ and a molecular weight of 123.11 g/mol. It occurs as colorless crystals or a white, crystalline powder that is odorless or almost odorless, with a melting point of 234–238°C. Niacin is sparingly soluble in water (1.67 g per 100 mL at 25°C), freely soluble in boiling water, soluble in 100 parts of ethanol, and practically insoluble in ether.
Niacin is an essential nutrient that serves as the precursor to the coenzymes nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+). NAD functions in intracellular respiration and as a codehydrogenase with enzymes involved in the oxidation of fuel molecules, while NADP functions in reductive biosyntheses such as fatty acid and steroid synthesis. Over 400 enzymes require NAD to catalyze reactions within the body, including those involved in glycolysis, the Krebs cycle, and the electron transport chain. Niacin is available in two primary forms for supplementation: nicotinic acid (niacin) and niacinamide. While both provide vitamin B3 activity, only nicotinic acid significantly affects cholesterol levels and causes flushing, whereas niacinamide is used primarily for skin health and DNA repair support without flushing. This product delivers the nicotinic acid form, which is the preferred form for cardiovascular and lipid regulation applications.
Conventional nicotinic acid presents significant formulation and bioavailability challenges. The compound undergoes rapid metabolism, has poor solubility, and causes off-target effects—particularly the characteristic flush—that limit patient compliance and therapeutic efficacy. The niacin flush is triggered by activation of the hydroxycarboxylic acid receptor 2 (HCA2) in subcutaneous blood vessels, leading to prostaglandin production and cutaneous vasodilation. This reaction can begin at supplemental doses as low as 30–50 mg of nicotinic acid, although sensitivity varies among individuals.
Liposomal encapsulation provides four critical advantages:
1. Significantly Enhanced Bioavailability and Plasma Retention — Liposomal delivery results in superior absorption of niacin. A randomized, double-blind, two-period crossover clinical trial enrolled 20 healthy Korean adults to assess the absorption of liposomal multinutrients compared to composition-matched non-liposomal comparators. Pharmacokinetic parameters including Cmax, Tmax, and incremental area under the curve (iAUC) were analyzed for vitamin B3. The pooled iAUC was 2–3.5× greater with liposomes, supporting improved short-term absorption. No clinically significant adverse events were observed during the study period.
2. Controlled Release and Reduced Flushing — The liposomal structure functions as a controlled-release system, allowing for sustained drug delivery over an extended period. Slow-release niacin formulations have a dissolution time of over 12 hours and reduced flushing compared to immediate-release niacin, whose peak blood levels are attained 30 to 60 minutes after administration. Liposomal encapsulation provides a similar sustained-release effect while protecting niacin from premature degradation.
3. Enhanced Stability and Protection — The phospholipid layer acts as a “protective shell,” effectively preventing active ingredients from degrading due to light, oxidation, or pH changes. B-complex vitamins, including niacin, are sensitive to light, pH conditions, and temperature, and liposomal encapsulation provides protection against these environmental stressors.
4. Reduced Toxicity and Improved Tolerability — By encapsulating niacin, liposomes can minimize systemic exposure to toxic metabolites, thereby reducing adverse effects. This is particularly important for niacin, which can cause hepatotoxicity at high doses of sustained-release formulations.
| Field | Details |
|---|---|
| Product Name | Liposomal Vitamin B3 Niacin 80% |
| CAS No. | 59-67-6 |
| EINECS No. | 200-441-0 |
| Active Ingredient | Nicotinic Acid (Niacin) |
| Assay Method | RP-HPLC with C18 column (250 mm × 4.6 mm, 5 µm); mobile phase 10 mM phosphate buffer pH 3.0:methanol (90:10, v/v); UV detection at 261 nm; sample preparation involves acid hydrolysis for food matrices. Alternative: LC-MS/MS with negative ion mode monitoring [M-H]- at m/z 122.0 for high-specificity quantification. Detection limit can reach 0.1 µg/mL |
| Purity | ≥ 80% niacin (liposomal loading); assay on dry basis 99.0%–101.0% available |
| Appearance / Color | White to off-white fine powder (liposomal form); colorless crystals or white crystalline powder (native form) |
| Odor | Odorless or almost odorless |
| Solubility | Sparingly soluble in water (1.67 g/100 mL at 25°C); freely soluble in boiling water; soluble in ethanol; practically insoluble in ether |
| Dosage Form | Liposomal powder, water-dispersible |
| Recommended Dosage | RDA: 16 mg NE/day for adult men and 14 mg NE/day for adult women; UL: 35 mg/day based on flushing as the critical adverse effect; therapeutic lipid doses 500–2,000 mg/day under medical supervision |
| Application | Energy Metabolism and NAD+ support, cardiovascular health (lipid regulation), DNA repair and cellular health, skin integrity, metabolic support, cognitive function |
| Extract Source | Synthetic (oxidation of nicotine or hydrolysis of nicotinonitrile); sunflower phospholipid liposomal carrier system |
| Molecular Formula | C₆H₅NO₂ |
| Molecular Weight | 123.11 g/mol |
| Melting Point | 234–238°C |
| pH (1 in 100 solution) | 2.7–3.4 |
| Lead Time | In stock: 3–5 business days; Bulk/custom orders: 2–3 weeks |
| Shipping Method | International Express (FedEx / DHL / UPS); air and sea freight available; worldwide shipping including remote areas |
| Storage | Store in a tightly closed, light-resistant container in a cool, dry place. Protect from light, heat, and moisture. Shelf life: 24 months under recommended conditions |
| Packaging | 1 kg/aluminum foil bag with two plastic bags inside; 25 kg/carton or fiber drum with aluminum foil bag inside |
High Purity — Standardized to ≥80% niacin in the liposomal formulation, with assay on dry basis of 99.0%–101.0% available.
Liposomal Enhancement — Randomized crossover clinical trial demonstrated 2–3.5× greater pooled iAUC for vitamin B3 compared to non-liposomal comparators, with significantly higher plasma concentrations in prespecified time windows.
NAD+ Precursor — Niacin is converted into NAD+, a coenzyme essential for over 400 enzymatic reactions, including glycolysis, the Krebs cycle, and electron transport. As a precursor of NAD+ and NADP+, niacin directly regulates metabolism and promotes cross-talk between environmental and energetic fluctuations.
Clinically Validated for Lipid Regulation — A meta-analysis of 22 RCTs demonstrated that niacin supplementation significantly reduced triglycerides (WMD: −33.4 mg/dL, p<0.001) and increased HDL cholesterol.
Controlled Release and Reduced Flushing — Liposomal encapsulation provides sustained release similar to extended-release niacin formulations, which have reduced flushing compared to immediate-release niacin.
DNA Repair and Cellular Health — NAD+ is essential for DNA repair, and niacin supports healthy DNA repair and skin integrity through PARP-mediated mechanisms.
Superior Stability — The phospholipid bilayer protects niacin from light, pH, and temperature-induced degradation.
Water-Dispersible — Liposomal powder offers excellent dispersibility in aqueous systems; suitable for capsules, tablets, powder drink mixes, and functional beverages.
Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.
| Application | Recommended Usage | Notes |
|---|---|---|
| Capsules / Tablets | 10–50 mg per serving | 1–2 capsules daily with meals; liposomal formulations typically provide 10–20 mg per serving |
| Functional Beverages | 5–20 mg per 250 mL | Water-dispersible; suitable for RTD formats |
| Powdered Drink Mixes | 20–100 mg per sachet | Best absorbed when taken with food |
| Energy Metabolism Formulas | 10–50 mg per serving | Often combined with other B vitamins (B1, B2, B6, B12) or CoQ10 |
| Cardiovascular Formulas | 50–150 mg per serving | Clinical lipid studies used 500–2,000 mg/day under medical supervision |
| NAD+ Support Formulas | 10–50 mg per serving | Often combined with NAD+ precursors or RESVERATROL |
The Recommended Dietary Allowance (RDA) for niacin is 16 mg/day of niacin equivalents (NEs) for adult men and 14 mg/day of NEs for adult women. During pregnancy and lactation, the requirement increases to 18 mg/day and 17 mg/day, respectively. The Tolerable Upper Intake Level (UL) for niacin for adults is 35 mg/day, which was based on flushing as the critical adverse effect. For supplemental use, many B-complex and multivitamin supplements provide 10–50 mg of niacin. Liposomal formulations may provide 10–20 mg of niacin per serving, with higher doses available for targeted applications. For lipid regulation, high-dose niacin (500–2,000 mg/day) is used under medical supervision and is available as an FDA-approved prescription drug (Niaspan) for lipid disorders. Clinical trials have used extended-release niacin tablets at 1,500–2,000 mg/day, with dosing ranging from 500 to 3,000 mg. The AIM-HIGH trial randomized participants to receive niacin extended-release tablets 1500–2000 mg/day (n=1,718) or matching placebo. A dose escalation protocol from 250 mg (week 1) to 500 mg (week 2) to 750 mg (weeks 3–12) has been used in clinical settings. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability and sustained release.
Important Safety Information: Niacin causes a flushing reaction characterized by warmth, redness, itching, or tingling of the skin, which can begin at doses as low as 30–50 mg. This reaction is harmless but can be uncomfortable. High-dose niacin (500–2,000 mg/day) can cause hepatotoxicity, hyperglycemia, and hyperuricemia, and should only be used under medical supervision with regular liver function monitoring. Individuals with active liver disease, active peptic ulcer, or arterial bleeding should not use high-dose niacin. Pregnant or lactating women and children should consult a healthcare professional before use. Niacin may interact with statins, anticoagulants, and diabetes medications. Liposomal niacin may reduce flushing compared to immediate-release niacin, but individual sensitivity varies.
Stock Orders: 3–5 business days after payment confirmation.
Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.
Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.
Coverage: Worldwide shipping, including remote areas.
Niacin (Vitamin B3) Encyclopedia — Scientific Background
Niacin (CAS 59-67-6), also known as nicotinic acid, pyridine-3-carboxylic acid, or vitamin B3, is a water-soluble vitamin with the molecular formula C₆H₅NO₂ and a molecular weight of 123.11 g/mol. It is chemically characterized as pyridine-3-carboxylic acid and occurs as colorless crystals or a white, crystalline powder. Niacin is odorless or almost odorless and has a mild acidic taste, with a melting point of 234–238°C. It is sparingly soluble in water (1.67 g per 100 mL at 25°C), freely soluble in boiling water, soluble in 100 parts of ethanol, and practically insoluble in ether.
| Property | Value |
|---|---|
| CAS No. | 59-67-6 |
| EINECS No. | 200-441-0 |
| Molecular Formula | C₆H₅NO₂ |
| Molecular Weight | 123.11 g/mol |
| IUPAC Name | Pyridine-3-carboxylic acid |
| Synonyms | Niacin, Nicotinic acid, Vitamin B3, Vitamin PP, 3-Picolinic acid |
| Appearance | Colorless crystals or white crystalline powder |
| Melting Point | 234–238°C |
| Solubility | Sparingly soluble in water (1.67 g/100 mL at 25°C); freely soluble in boiling water; soluble in ethanol |
| Assay (Dry Basis) | 99.0%–101.0% |
| UV Absorption | ~261 nm |
Vitamin B3 exists in two primary forms used in supplementation:
Nicotinic Acid (Niacin) — This is the form that significantly affects cholesterol levels and causes the characteristic flush. The flush is triggered by activation of the hydroxycarboxylic acid receptor 2 (HCA2) in subcutaneous blood vessels, leading to prostaglandin production and cutaneous vasodilation. Niacin lowers LDL cholesterol and triglycerides while raising HDL cholesterol. High-dose niacin (Niaspan) is FDA-approved as a prescription drug for lipid disorders.
Niacinamide (Nicotinamide) — This form provides B3 activity but does not cause flushing and does not significantly affect cholesterol levels. It is used primarily for skin health and DNA repair support.
Both forms are converted into NAD+ in the body, and biological responses are virtually equivalent when taken in common doses. However, only nicotinic acid has the lipid-regulating effects that make it valuable for cardiovascular applications.
Niacin is converted into nicotinamide adenine dinucleotide (NAD+) and its phosphate form (NADP+), which are critical for redox reactions in glycolysis, the Krebs cycle, and the electron transport chain. Over 400 enzymes require NAD to catalyze reactions within the body. NAD functions in intracellular respiration and as a codehydrogenase with enzymes involved in the oxidation of fuel molecules such as glyceraldehyde 3-phosphate, lactate, alcohol, 3-hydroxybutyrate, pyruvate, and α-ketoglutarate. NADP functions in reductive biosyntheses such as in fatty acid and steroid syntheses and, like NAD, as a codehydrogenase—as in the oxidation of glucose 6-phosphate to ribose 5-phosphate in the pentose phosphate pathway. NAD is also required for important nonredox ADP-ribose transfer reactions involved in DNA repair and calcium mobilization.
Niacin’s lipid-modifying effects are mediated through multiple mechanisms, including inhibition of hepatic triglyceride synthesis, reduction of VLDL secretion, and decreased catabolism of HDL. A meta-analysis of 22 randomized controlled trials demonstrated that niacin supplementation significantly reduced triglycerides (WMD: −33.4 mg/dL, p<0.001) and increased HDL cholesterol. A post-hoc analysis of the AIM-HIGH trial (n=3,414) found that while niacin effectively raises HDL and lowers triglycerides, adding it to intensive statin therapy did not further reduce major vascular events in that population. Niacin therapy at 750 mg and 1.5 g/day resulted in a significant rise in HDL-C by 8.10 ± 3.19 and 12.41 ± 4.39 per cent (P<0.001), respectively.
Niacin-induced flushing is triggered by activation of the hydroxycarboxylic acid receptor 2 (HCA2), also known as GPR109A, in subcutaneous blood vessels. This activation starts a signaling cascade that releases prostaglandins, especially PGD2, which causes cutaneous vasodilation. Furthermore, niacin directly interacts with the transient receptor potential (TRP) channel TRPV1, offering a different, non-prostaglandin-based explanation for flushing brought on by niacin. This reaction is harmless but can be uncomfortable, with warmth, redness, itching, or tingling that begins at supplemental doses around 30–50 mg. Slow-release niacin formulations have a dissolution time of over 12 hours and reduced flushing.
NAD+ is essential for DNA repair through poly-ADP-ribose polymerase (PARP)-mediated mechanisms. PARP is found in the nuclei of eukaryotic cells and catalyzes the transfer of many ADP-ribose units from NAD to an acceptor protein and also to the enzyme itself. These nuclear poly-ADP-ribose proteins seem to function in DNA replication and repair. Niacinamide (a related form of vitamin B3) has been shown to significantly reduce the rate of new non-melanoma skin cancers by 23% (p=0.02) after 12 months in a randomized controlled trial of 386 adults with skin cancer history. This effect is attributed to NAD+‘s role in DNA repair and cellular Energy Metabolism.
Despite its essential physiological functions, conventional nicotinic acid presents significant bioavailability challenges. The compound undergoes rapid metabolism, has poor solubility, and causes off-target effects—particularly the flushing reaction—that limit patient compliance. Immediate-release niacin achieves peak blood levels 30 to 60 minutes after administration, causing a pronounced flush that can be uncomfortable. After an oral dose of 1000 mg of nicotinic acid, plasma levels of free nicotinic acid peak at 0.5–1 hour at 30 μg/mL, with a plasma elimination half-life of 20 to 45 minutes. While extended-release formulations reduce flushing, they have been associated with hepatotoxicity at high doses.
These limitations have driven the development of advanced delivery systems, including liposomal encapsulation. A randomized, double-blind, two-period crossover clinical trial demonstrated that liposomal multinutrient formulations achieved 2–3.5× greater pooled iAUC for vitamin B3 compared to non-liposomal comparators, with significantly higher plasma concentrations in prespecified time windows.
Liposomal encapsulation of niacin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the niacin molecule, forming a protective shell that enhances stability, bioavailability, and cellular uptake. This delivery system:
Achieves 2–3.5× greater pooled iAUC for vitamin B3 compared to non-liposomal comparators in a randomized crossover clinical trial
Results in significantly higher plasma concentrations in prespecified time windows
Protects niacin from enzymatic degradation and enhances its absorption in the gastrointestinal tract
Provides controlled release similar to extended-release formulations, potentially reducing flushing while maintaining efficacy
Prevents active ingredients from degrading due to light, oxidation, or pH changes
The lipid bilayer of liposomes acts as a controlled-release system, allowing for sustained drug delivery over an extended period. This is particularly advantageous for niacin, where the goal is to maximize therapeutic benefit while minimizing the flushing response and other off-target effects.
A meta-analysis of 22 randomized controlled trials evaluated the effects of niacin supplementation on lipid parameters. Niacin significantly reduced triglycerides (WMD: −33.4 mg/dL, p<0.001) and increased HDL cholesterol. These findings support the well-established role of nicotinic acid in lipid management.
The AIM-HIGH trial was a randomized controlled trial of 3,414 participants with established cardiovascular disease who were treated with simvastatin with or without niacin. Participants were randomized to receive niacin extended-release tablets 1500–2000 mg/day (n=1,718) or matching placebo (IR Niacin, 100–150 mg). While niacin effectively raised HDL and lowered triglycerides, adding it to intensive statin therapy did not further reduce major vascular events in this population.
A double-blind, randomized, placebo-controlled design study assigned 18 sedentary yet otherwise healthy older (65–75 years) males to 2 weeks of nicotinic acid (acipimox; 250 mg × 3 daily, n=8) or placebo (n=10) supplementation. The study demonstrated that nicotinic acid improves mitochondrial function and associated transcriptional pathways in older inactive males.
A randomized controlled trial (ONTRAC) of 386 adults with a history of skin cancer found that 500 mg of niacinamide twice daily significantly reduced the rate of new non-melanoma skin cancers by 23% (p=0.02) after 12 months. This effect is attributed to NAD+‘s role in DNA repair and cellular energy metabolism.
Niacin has a well-established safety profile when used appropriately. The Tolerable Upper Intake Level (UL) for niacin for adults is 35 mg/day, which was based on flushing as the critical adverse effect. High-dose niacin (500–2,000 mg/day) can cause hepatotoxicity, hyperglycemia, and hyperuricemia, and should only be used under medical supervision with regular liver function monitoring.
Regulatory Status:
United States — Niacin is an essential nutrient with a Daily Value (DV) of 16 mg. High-dose niacin (Niaspan) is FDA-approved as a prescription drug for lipid disorders. Niacin is Generally Recognized As Safe (GRAS) for use in food and dietary supplements.
European Union — Niacin is authorized as a food supplement ingredient and is permitted for use in food fortification in EU member states. The European Food Safety Authority (EFSA) has established health claims for niacin, including contributions to normal energy-yielding metabolism, normal functioning of the nervous system, and normal skin maintenance. The EU Scientific Committee for Food has set an upper limit for nicotinic acid of 10 mg/day for adults.
Global Standards — Niacin is monographed in the USP, European Pharmacopoeia, and Japanese Pharmacopoeia. The product is available with Halal and Kosher certifications.
Precautions: Niacin causes a flushing reaction that is harmless but can be uncomfortable. High-dose niacin should only be used under medical supervision. Individuals with active liver disease, active peptic ulcer, or arterial bleeding should not use high-dose niacin. Pregnant or lactating women and children should consult a healthcare professional before use. Niacin may interact with statins, anticoagulants, and diabetes medications.
Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.
This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.
89$/KG
RELATED
RELATED
RELATED
RELATED
This website uses cookies to ensure you get the best experience on our website.
Español
Français
Deutsch
日本語
한국어
Phone
Comment
（0）